Zai Lab targets major 2027 milestones for Zoci

Zai Lab targets major 2027 milestones for Zoci
Zai Lab projects completing Phase III enrollment for its lead candidate Zoci in the first half of 2027, with an FDA biologics license application submission expected in late 2027. The biotech company faces near-term headwinds from China sales pressure and supply constraints that are impacting current operations. Despite these challenges, management remains focused on advancing its clinical pipeline and expanding market presence. The company's 2026-2027 outlook reflects confidence in Zoci's development trajectory, though execution risks remain tied to enrollment pace and manufacturing capabilities. Investors should monitor upcoming trial data and supply chain updates as key catalysts for stock movement in coming quarters.